Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.02.28.708687

Clinical Metabolomics studies in diagnosing Prediabetes and Type 2 Diabetes: Unveiling Trends through Bibliometric Analysis

Abstract

BackgroundPrediabetes is the transitional stage preceding the onset of type 2 diabetes. Due to its asymptomatic nature and slow progression, conventional screening methods frequently fail to identify individuals in this prediabetic stage. Therefore, this study employs bibliometric methods to reveal the abnormal changes in clinically relevant metabolites in diabetes, providing evidence for early diagnosis, pathogenesis, and precision interventions. MethodsSearch the Web of Science Core Collection database for all papers on metabolomics related to prediabetes and type 2 diabetes clinical research from the databases inception until May 2025. Use VOSviewer and CiteSpace software to perform bibliometric analysis on the included literature. ResultsA total of 1,742 studies were ultimately included in the review of the literature. Researchers from China, the United States, and Germany, as well as institutions, have made significant contributions to metabolomics research in prediabetes and type 2 diabetes. The highest number of publications and citations was from the journals Metabolites and Diabetes. The current research hotspots in this field, as determined by keyword co-occurrence and clustering analysis, include metabolomics, insulin resistance, obesity, risk factors, biomarkers, gut microbiota, amino acids, lipidomics, and mass spectrometry. ConclusionThe outcomes of the study are instrumental in enabling scholars to comprehend the developmental trajectory of metabolites associated with prediabetes and type 2 diabetes and facilitate the rapid identification of emerging research pathways.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Li, M., Sun, M., Yao, L., Wang, W., Mei, J., Huang, X., Zhang, X., Lian, Z., Le, T. T. V., He, M., Wang, H.. 2026-03-03. Clinical Metabolomics studies in diagnosing Prediabetes and Type 2 Diabetes: Unveiling Trends through Bibliometric Analysis. https://doi.org/10.64898/2026.02.28.708687

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Common viral infections seed regionally distinct resident memory T cells in the human CNS

T cells persist in the central nervous system (CNS) and can drive both protection and neurological disease. How these cells are organized in humans and what they recognize is largely unknown. Here, we profiled CD8 T cells across anatomically distinct CNS regions, obtained through on-site autopsies and temporal lobe resection surgeries, using single-cell RNA sequencing, paired T cell receptor sequencing, and DNA-barcoded tetramers. Resident memory T cells (TRM) specific for Epstein-Barr virus, cytomegalovirus, influenza A, and SARS-CoV-2 were identified across CNS compartments. Anatomical location was the strongest correlate of TRM cell state, with leptomeningeal cells adopting a cytokine-poised TRM program, whereas brain TRM cells were transcriptionally restrained. Cells of the same clonotype spanned tissues yet adopted local transcriptional states. Viral specificity added another layer of TRM heterogeneity with GZMK/GZMA-expressing EBV-specific populations and interferon-stimulated gene signatures in SARS-CoV-2 and Influenza A-specific cells. The human CNS thus harbors regionally distinct CD8+ TRM shaped by common viral exposures.

immunology↗

A regulatory T cell signature provides a shared molecular basis for the therapeutic window of opportunity in rheumatic disease

Rheumatic diseases, including rheumatoid arthritis (RA), spondyloarthritis (SpA) and osteoarthritis (OA), show distinct phenotypes yet respond to overlapping therapies, implicating shared immune mechanisms. In the Transimmunom cohort, we profiled peripheral blood from 240 individuals (47 healthy, 44 OA, 91 RA, 58 SpA) across deep immunophenotyping, immunoproteomics and Treg-Teff transcriptomics. Single-layer analyses revealed broader Treg than Teff remodeling, along with a shared pattern of reduced activated Tregs and expanded Helios+ Tregs across all diseases, alongside a decrease in functional Treg subpopulations, including CTLA4+ and CD45RA- Tregs. In RA specifically, LAG3+ Tregs were also expanded. Combining omics layers outperformed single-layer approaches for disease classification. Among individual layers, Treg transcriptomes were most discriminative, and integration uncovered disease-specific programs. Unsupervised clustering identified a cross-disease cluster independent of activity, treatment and age, mapping to early disease (<= years) and dominated by a Treg dysfunction-associated program. These results provide a biological rationale for the therapeutic "window of opportunity" concept and duration-stratified Treg-directed trials.

immunology↗

Inhibitory Fc Receptor sets a time limit on macrophage response to IgG

Antibodies engage both activating Fc Receptors and the inhibitory receptor Fc{gamma}RIIB. Why macrophages need a dedicated inhibitory receptor rather than simply tuning activating receptor signaling is unclear. Using DNA-based chimeric receptors and in silico modeling, we independently controlled activating and inhibitory Fc Receptors. We found that Fc{gamma}RIIB imposed a time limit on macrophage phagocytosis and ERK signaling. The time limit is due to activating Fc Receptors converting PI(4,5)P2 to PI(3,4,5)P3, which is subsequently converted to PI(3,4)P2 by Fc{gamma}RIIB. This leads to a pulse of active signaling, which is sufficient for phagocytosis of small bacteria-sized targets but not phagocytosis of large targets and TNF secretion. Unlike engaging Fc{gamma}RIIB, reducing activating Fc Receptor signaling decreased initiation of phagocytosis, the speed of PI(3,4,5)P3 generation, and the amplitude of ERK signaling. Our results demonstrate that Fc{gamma}RIIB controls the duration of IgG signaling, while the activating Fc Receptors control sensitivity.

immunology↗